Zhejiang Huahai Pharmaceutical has filed a patent for an isolated antigen-binding protein that binds to CD73, containing specific amino acid sequences. The patent also includes a method for preparing the protein and its application. GlobalData’s report on Zhejiang Huahai Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zhejiang Huahai Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Huahai Pharmaceutical's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Antigen-binding protein binding to cd73 with specific amino acid sequences
The patent application (Publication Number: US20240026024A1) discloses an isolated antigen-binding protein that includes specific amino acid sequences in the HCDR3, HCDR2, and HCDR1 regions, as well as the LCDR3, LCDR2, and LCDR1 regions. The protein also comprises VH and VL regions with defined amino acid sequences. Additionally, the antigen-binding protein includes heavy and light chain constant regions derived from human IgG and Ig? constant regions, respectively. Furthermore, the protein is capable of specifically binding to CD73 or its active fragments, inhibiting CD73 enzymatic activity, and inducing endocytosis of CD73 on cell surfaces.
Moreover, the patent application describes the use of the isolated antigen-binding protein in various applications, including as a polypeptide molecule, a fusion protein, an immunoconjugate, and a component of pharmaceutical compositions. The application also outlines methods for preventing, relieving, and treating CD73-mediated diseases and disorders, such as breast cancer, by administering the antigen-binding protein. Additionally, a method for detecting CD73 in samples using the isolated antigen-binding protein is disclosed, highlighting the protein's potential diagnostic applications in identifying CD73-related conditions.
To know more about GlobalData’s detailed insights on Zhejiang Huahai Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
